Antibody-mediated rejection has emerged as one of the major issues limiting the success of organ transplantation. It exerts a highly negative impact on graft function and outcome, and effective treatment is lacking. The triggers for antibody development, and the mechanisms leading to graft dysfunction and failure, are incompletely understood. The production of antibodies is dependent on instructions from various immunocytes including CD4 T-helper cells that secrete interleukin (IL)-21 and interact with antigen-specific B-cells via costimulatory molecules. In this article, we discuss the role of IL-21 in the activation and differentiation of B-cells and consider the mechanisms of IL-21 and B-cell interaction. An improved understanding of the biological mechanisms involved in antibody-mediated complications after organ transplantation could lead to the development of novel therapeutic strategies, which control humoral alloreactivity, potentially preventing and treating graft-threatening antibody-mediated rejection.
is a typical family I cytokine with broad pleiotropic actions and is primarily produced by T follicular helper cells (Tfh), Th17, and natural killer T-cells, rather than being generally produced by most tissue cells (6, 8, 9) . IL-21 controls the activation, proliferation, differentiation, cytotoxicity, and survival of various target immune cells (10, 11) . It is also important for the generation of B-cell responses in germinal centers resulting in isotype switching, affinity maturation, antibody production, and development of B-cells (12, 13) . In particular, IL-21-mediated actions by Tfh cells are required for efficient antibody responses. The effectors and immune regulatory functions of IL-21 are mediated by binding to target B-cell surface receptors, which consist of α-chain and the γc that is shared with IL-2, IL-4, IL-7, IL-9, and IL-15 receptors (10, 14, 15) .
Antibody-mediated ("humoral") rejection is a key cause of graft dysfunction and failure after organ transplantation (1, 16, 17) with 30-50% of failed allografts affected (18) (19) (20) . Immunohistochemical and gene expression studies have shown that a large number of B-cells infiltrate the rejected allograft (18, (21) (22) (23) (24) , contributing to anti-donor responses.
Identifying the role of IL-21-mediated B-cell activation and differentiation pathways is critical for understanding the signaling pathways that underlie antibody-mediated rejection. In this review, we discuss the potential role of IL-21 on B-cells after organ transplantation.
iL-21 SiGNALiNG PATHwAY iN B-CeLLS
The IL-21R is expressed by human naive B-cells, memory B-cells, germinal center B-cells (14), and as shown recently, plasma cells (25) . IL-21R is upregulated on human memory B-cells after activation by anti-CD40 mAb (14).
Binding of IL-21 with IL-21R/γc triggers the catalytic activation of JAK1 and JAK3. This causes phosphorylation of tyrosine residues on IL-21R/γc, providing docking sites for STAT proteins and other signaling molecules (26) . On recruitment, STATs are phosphorylated and form homodimers or heterodimers, which translocate into the nucleus and modulate expression of the target genes (27) , which regulate B-cells, such as B-cell-induced maturation protein-1 (Blimp-1) (28), B-cell lymphoma (BCL)-6 (29), activation-induced cytidine deaminase (AID) (30) , granzyme (31) , somatic hypermutation (SHM) (32) , paired box 5 (Pax5) (33), X-box-binding protein 1 (XBP-1) (34), and Bim (35) . IL-21 mediates B-cell proliferation, immunoglobulin (Ig) production, and apoptotic functions mainly through the potent effects of STAT3 and/or STAT1 activation but also, to a lesser extent, through STAT4 and STAT5 (36) (37) (38) (39) (Figure 1) .
B-CeLL ACTivATiON AND DiFFeReNTiATiON
B-cell receptor (BCR) ligation triggers activation of multiple downstream molecules. Burton's tyrosine kinase (Btk), one of the downstream products of the BCR signaling pathway, selectively regulates IL-21-induced STAT1 phosphorylation and translocation in the nucleus. Btk deficiency is associated with arrested cell development at the pre-B-cell stage. In addition, Btk is involved in cytokine-controlled B cell activation. In concert with IL-21, CD40, and B-cell activating factor (BAFF), this kinase mediates the crosstalk with cytokine pathways through regulation of IL-21-induced phosphorylation of STAT1 (25) . IL-21 and CD40L collaborate to synergistically promote Blimp-1 activation and plasma cell differentiation (28) . CD40L alone has no direct effect on Blimp-1, but it greatly augments the IL-21-triggered JAK-STAT signaling. During this phase, STAT3 plays a more significant role than STAT1, because STAT3 mutations dramatically reduce the number of memory B-cells and abolish the ability of differentiation of naive B-cells into plasma cells (10) . In contrast, STAT1 deficiency has no effect on memory B-cell formation in vivo. Thus, STAT3 is essential for the generation of effector memory B-cells from naive precursors (40) . In addition, treatment with CD40L enhances the ability of STAT3 to upregulate Blimp-1 by removing BCL-6, which is a potent inhibitor of Blimp-1 expression. It has been speculated that IL-21 induces Blimp-1 and BCL-6 to regulate isotype-switched B-cells (41) . Blimp-1 is a transcription factor and involved in plasma cell formation and maturation (42) . Importantly, IL-21 costimulation upregulates expression of Blimp-1 (43) . Consistent with this, IL-21-driven plasma cell differentiation from both naive blood B-cells and from memory B-cells are preceded by induction of Blimp-1 upregulation. Blimp-1 initiates plasma cell differentiation by downregulating MHC, CIITA, Pax5, and c-myc expression (33, 44, 45) and by inducing XBP-1 expression (46, 47) . Blimp-1 level is very low when BCL-6 is over-expressed in B-cells (48) . BCL-6 may block plasma cell differentiation due to downregulation of Blimp-1 (49). BCL-6 also can control B-cell development by BTB and RD2, two molecules that repress distinct functional effects of B-cells during the germinal centers reaction. BTB is required for B-cell survival and proliferation, while RD2 might be important for the prevention of terminal B-cell differentiation (50).
Since IL-21 activates STAT3 in B-cells, this may indicate that activation of STAT3 in human B-cells is pivotal for the induction of Blimp-1 expression and plasma cell differentiation (11, 40) . It has been reported that IL-21-dependent CD86 upregulation is reliant on STAT3 phosphorylation and PI3K, revealing unexpected roles for these pathways in IL-21-mediated B-cell responses (51) . In addition, IL-21 drives humoral immune responses via STAT3-dependent induction of the transcription factors required for plasma cell generation (52) . These authors reported that IL-21via STAT3 sensitizes B-cells to the stimulatory effects of IL-2. Thus, IL-2 plays an adjunctive role in IL-21-induced B-cell differentiation. An absence of this secondary effect of IL-21 may amplify humoral immunodeficiency in patients with mutations in STAT3 and IL-21R due to impaired responsiveness to IL-21. In concert, IL-21 and BAFF stimulate and may maintain humoral immunity in humans (53) . BAFF has the ability to substitute for CD40L activity with regards to IL-21 costimulation and differentiation of memory B-cells present in spleen (53) (Figure 2 ).
iMMUNOGLOBULiN PRODUCTiON
Critical sites for the generation of antibody responses are the germinal centers in lymphoid follicles present in lymph nodes that also have been identified in transplanted organs (4, 54) where antigen-primed B-cells interact with T-cells, most of which are Tfh cells secreting IL-21. The B-cells are driven to undergo Ig isotype FiGURe 3 | immunoglobulin (ig) production. Ig is produced by plasma cells, so the signaling pathway for mediation of Ig production is similar to that for IL-21-mediated plasma cell maturation. Some molecules, however, have a specific role in Ig production: BMP-2, -4, -6, and -7 may exert a negative influence and Btk a positive influence. In addition, some cytokines contribute to Ig CSR. IL-4 can induce to IgG1 formation, IFN-γ to IgG2a, and IL-10 to IgA. switching, with SHM and secretion of high affinity antibodies (12, (55) (56) (57) (58) (56, 57, (59) (60) (61) (62) . It has been reported that IgM-specific Abs targeting BCR and IL-21 costimulation also induce the expression of AID (63, 64) . Interestingly, although AID catalyzes both class switch recombination (CSR) and SHM, only CSR is induced in naive human B-cells after stimulation by IL-21 and anti-CD40 (45, 47, 60, 65) . The C-terminal of AID is required for CSR but not for SHM (65, 66) , and it has been postulated that IL-21 induces AID activity only at the C terminus. Multiple studies have shown that IL-21 causes CSR of CD40-stimulated human naive splenic IgM + B-cells to IgG1 and IgG3, and CSR of CD40-stimulated cord blood B-cells to IgA (47, 60) . As well as the molecules described above, among the group of cytokines called bone morphogenetic proteins (BMPs) (67), BMP-2, -4, -6, and -7 inhibit CD40L/IL-21-induced production of IgM, IgG, and IgA. In memory B-cells, BMP-6 upregulated expression of DNA-binding protein inhibitor genes, but potently inhibited CD40L/IL-21-induced upregulation of the transcription factor XBP-1 (34) . This factor is crucial for final stage in plasma cell differentiation (34). As described above, Btk is an efficient propagator of IL-21 signaling, critical for CSR in human B-cells and secretion of Ig (25) . Additionally, the outcome of IL-21-mediated Ig secretion depends on the presence of IL-4 and IL-10, which influence the outcome of IL-21-mediated CSR. IL-10 acts synergistically with IL-21 to induce secretion of IgA by CD40L-stimulated human B-cells, whereas IL-4 has an inhibitory effect (47) . As shown by the group of Bromberg, IL-10 deficiency in B-cells prevents transplantation tolerance, resulting in decreased follicular immune regulatory CD4
+ T-cells, a recently identified T cell subset, and increased IL-21 expression by Tfh cells in the B-cell and T-cell marginal zones (68) . This has implications for our understanding of the mechanisms involved in tolerance and show at the same time that B cells play pivotal roles in the induction of this immune phenomenon (68) . Interestingly, as with IL-21, IL-10, in combination with toll-like receptor (TLR), signaling also enhances phosphorylation of STAT3, resulting in increased IgG production. Hence, IL-21 and IL-10 increase the activity of the TLR-MyD88-STAT3 pathway in human B-cells by enhancing Ig production stimulated by STAT3 phosphorylation (69) (Figure 3 ).
ReGULATORY B (B10) CeLLS
Interleukin-21 may also modulate the immune response by immune-dampening regulatory mechanisms. One of these is performed by B10 cells, named for their ability to produce abundant + B-cell subset, and approximately 60% also express CD38 (73) . B10 progenitors and B10 cells have been identified in human (73) . Ex vivo, human B10 progenitors can be driven to develop into B10 cells by lipopolysaccharide (LPS) or 5′-C-phosphate-G-3′ (CpG), or by CD40 ligation. In vitro, IL-21/CD40-receptor signaling pathways can promote the development and expansion of B10 cells by four million-fold to suppress the immune response. IL-21R signaling, together with major histocompatibility complex class II and CD40 cognate, interacts with CD4 + T-cells and although not required for B10 cell development, are necessary for B10 cell effector functions that result in antigen-specific responses. Interestingly, BCR ligation augments human B-cell IL-10 responses to CpG (74) . Whether human B10 cells develop into antibody-secreting cells, or enter the memory B10 cell subset, remains to be determined (75) . B10 cells may represent a subset, which is similar to regulatory T-cells (76) (Figure 4) . B10 cells are able to control the immune response, but an excessive reaction from these cells may also promote tumor cell growth or chronic infection (77) . It is possible that regulatory fine tuning by B-cells and IL-21 production by T-cells might be a key factor in maintaining immune tolerance (78) . Most investigations of B10 cells have concentrated on autoimmune diseases (79) , but a few have assessed their role in transplantation (80) . A mouse islet T-cell transplantation study has demonstrated that B10 cells control immune responses (81).
B-CeLL APOPTOSiS MeDiATeD BY iL-21
The effects of IL-21 on B cells depend on the costimulatory signals that are received. In the absence of signal from a T cell (such as the T cell engaging CD40), BCR activation is required for IL-21-mediated B cell apoptosis (15, 29, 35) . The balance between STAT1 and STAT3 is critical for IL-21-induced B-cell apoptosis in the IL-21 signaling pathway. STAT1 mainly acts in cell cycle arrest and apoptotic cell death (45, 47, 82, 83) . By contrast, STAT3 mostly exerts an anti-apoptotic effect, especially in numerous malignancies where it is constitutively active (83) 
iL-21 AS A POSSiBLe PLAYeR iN ALLOReACTiviTY AFTeR TRANSPLANTATiON
Antibody-mediated rejection is a major problem after organ transplantation mediated by anti-HLA antibodies and donorspecific antibodies (DSA). This poorly defined alloimmune response is refractory to treatment with conventional immunosuppression (1). From our recent studies, we know that in this process, B-cells can be activated by IL-21-producing Tfh cells and differentiate into Ig-producing plasma cells. We reported that these Tfh cells as well as B-cells infiltrate the allograft during rejection and colocalize in follicular-like structures in the transplanted kidney (4, 18) . These tide clusters of T and B-cells form highly organized lymphoid structures named tertiary lymphoid organs (TLOs). Associations between the presence of these TLO and poor graft outcome have been reported (90) (91) (92) . In contrast, Xu et al. reported that IL-17, and not IL-21, is responsible for lymphoid neogenesis. Therefore, they suggested that Th17, but not Tfh, cells could play a role in the process of lymphoid neogenesis (93) . The first approach is speculative and based on the finding that IL-21 induces B-cell apoptosis when costimulation signals are absent (15, 29, 35) . At the same time, IL-21 might stimulate the cytolytic functions of alloantigen activated CD8 T cells, the aggressors in acute rejection (96, 97) . Therefore, we should be careful with IL-21 cytokine treatment. This strategy should first be tested in experimental animal models by using various concentrations of IL-21 to define if B cell apoptosis and T cell cytotoxicity rely on the same or different concentrations of IL-21. This knowledge is helpful to better understand the role of IL-21 in B-cell-mediated immune processes such as apoptotic cell death.
The second approach could be blockade of the IL-21 pathway proven to affect the production of pathogenic immunoglobulins in animal models of autoimmune diseases. In these studies, blockade of the IL-21R signaling pathway reduced B-cellmediated diseases (98) . Also, in a mouse model of islet transplantation, mIL-21R-Fc combined with CTLA-4-Ig diminished T-cell and B-cell effector functions, and tolerance was induced in a subgroup of treated animals (99) . It is critical to determine whether neutralizing the IL-21 function also inhibits production of anti-HLA antibodies and DSA in organ transplant recipients. So far, such studies have not been conducted, but based on the biological functions of IL-21, the promising findings in animal models for autoimmune diseases and in vitro studies, targeting the IL-21 pathway could be expected to reduce the incidence of antibody-mediated alloreactivity. Our studies using peripheral T-cells and B-cells derived from kidney transplant patients showed that the interaction between IL-21-producing Tfh cells and B-cells could be inhibited by an IL-21 receptor antagonist. In these co-cultures, B-cell differentiation and IgM and IgG production were diminished (4). We believe that IL-21-producing Tfh cells play a dominant role in alloreactivity and should be targeted by novel immunosuppressive agents.
Like many other cytokines, IL-21 has multiple functions. In addition to its actions in B-cell apoptosis and differentiation it also drives regulatory B10 responses. These cells have been shown to suppress T-cell-mediated rejection induced by mismatched MHC molecules and prolong allogeneic islet T-cell survival, suggesting a potential regulatory role for B10 cells in organ transplantation (80, 81) . Since IL-21 can promote regulatory B10 cell proliferation, harnessing the anti-inflammatory properties of B10 cells by anti-IL-21 agents could potentially stimulate antibody-mediated rejection and promote a less favorable tolerogeneic environment by modulating the plasma cell/Breg (B10) balance (68) (Figure 7) . Recently, another type of Bregs was described, which could be inhibited by anti-IL-21 treatment. The number of GrB-producing B-cells with regulatory properties was significantly higher in tolerant patients compared to patients with stable graft function (78) . This observation suggests that targeting the IL-21R pathway with immunosuppressive agents may harness this cell population. Data in this area, however, remain sparse.
CONCLUSiON
In general, IL-21 promotes humoral immunity, and IL-21 blockade may attenuate B-cell hyperactivity in which also costimulatory signals are involved. However, B-cells may have a dual effect, acting both as a driver and as a regulator of the immune system (78, 79, 100) . In B-cells that recognize Ag and receive T-cell help, IL-21 induces survival, proliferation, isotype switching, and differentiation to Ig-secreting plasma cells or GrBproducing B-cells. B-cells can also cause cell death or, in the form of regulatory B10 cells, can induce autoimmunity if they receive a strong signal via BCR, or via TLR, and IL-21 costimulation. An equilibrium between effector and suppresser cells is necessary to maintain B-cell homeostasis and the immune balance, especially for the prevention of antibody-mediated transplantation rejection. Future studies should focus on elucidating details of the signaling cascades and downstream changes in gene and protein expression within B-cells in response to IL-21, either alone or in combination with other molecules. This knowledge may ultimately lead to an effective therapeutic strategy to overcome antibody-mediated rejection following transplantation, particularly by targeting the differentiation of B-cells into plasma cells via IL-21 signaling pathways.
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